Alterity Therapeutics (ATHE) “announced that several oral and poster presentations related to Alterity’s clinical programs in Multiple System Atrophy were featured at the 2025 International MSA Congress. The Congress was presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics has several presentations featured at 2025 MSA Congress
- Biotech Alert: Searches spiking for these stocks today
- Alterity Therapeutics management to meet with Maxim
- Alterity Therapeutics granted U.S. FDA Fast Track designation for ATH434
- Alterity Therapeutics Reports Positive Phase 2 Trial Results for MSA Treatment